We narrowed to 226 results for: ica;

#128317-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-JRGECO1a (#128317). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-JRGECO1a plasmid DNA. EF1a-driven, Flp-dependent expression of the biosensor jRGECO1a. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

March 18, 2024

Academic Institutions and Nonprofits only

#162375-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-jGCaMP8m-WPRE (#162375). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP8m-WPRE plasmid DNA. Syn-driven expression of calcium sensor GCaMP8m (faster, more sensitive). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

March 20, 2024

Academic Institutions and Nonprofits only

#162380-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-CAG-FLEX-jGCaMP8s-WPRE (#162380). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP8s-WPRE plasmid DNA. CAG-driven, Cre-dependent expression of calcium sensor GCaMP8s (more sensitive). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

June 22, 2021

Academic Institutions and Nonprofits only

#218874-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-iGABASnFR2-WPRE (#218874). In addition to the viral particles, you will also receive purified pGP-AAV-syn-iGABASnFR2-WPRE plasmid DNA. Syn-driven expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al eLife. 2026 Mar 18;14:RP108319. doi: 10.

Sept. 27, 2024

Academic Institutions and Nonprofits only

#163505-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP11390-pAAV-DLX2.0-minBG-SYFP2-WPRE3-BGHpA (Alias: CN1390) (#163505). In addition to the viral particles, you will also receive purified AiP11390-pAAV-DLX2.0-minBG-SYFP2-WPRE3-BGHpA (Alias: CN1390) plasmid DNA. AAV vector for strong and rapid SYFP2 expression in forebrain GABAergic interneurons. The enhancer core sequence has 100% sequence conservation between mouse and human. Developed especially for rapid viral labeling in human and NHP organotypic brain slice culture. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Aug. 17, 2022

Academic Institutions and Nonprofits only

#111066-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-dLight1.1 (#111066). In addition to the viral particles, you will also receive purified pAAV-hSyn-dLight1.1 plasmid DNA. hSyn-driven expression of dLight1.1 dopamine sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

Oct. 28, 2021

Academic Institutions and Nonprofits only

#123308-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-GRAB_NE1m (#123308). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_NE1m plasmid DNA. Synapsin-driven expression of GRAB-NE1 norepinephrine sensor. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Feng et al Neuron. 2019 May 22;102(4):745-761.e8. d

Nov. 4, 2019

Academic Institutions and Nonprofits only

#84446-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

March 18, 2024

Academic Institutions and Nonprofits only

#112677-AAV8

Ready-to-use AAV8 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Sept. 8, 2020

Academic Institutions and Nonprofits only

#125560-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-dLight1.3b (#125560). In addition to the viral particles, you will also receive purified pAAV-CAG-dLight1.3b plasmid DNA. CAG-driven expression of dLight1.3b dopamine sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

May 6, 2021

Academic Institutions and Nonprofits only

#112677-AAV1

Ready-to-use AAV1 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Dec. 2, 2019

Academic Institutions and Nonprofits only

#174378-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-syn-Flpo (#174378). In addition to the viral particles, you will also receive purified pAAV-syn-Flpo plasmid DNA. Syn-driven expression of the recombinase FLPo. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Jin et al Nat Neurosci. 2024 Jan 11. doi: 10.1038/

Oct. 21, 2024

Academic Institutions and Nonprofits only

#179463-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-JEDI-2P-Kv-WPRE (#179463). In addition to the viral particles, you will also receive purified pAAV-hSyn-JEDI-2P-Kv-WPRE plasmid DNA. hSyn-driven expression (soma and AIS-localized) of the genetically encoded voltage indicator JEDI-2P. These AAV preparations are suitable purity for injection into animals.

Francois St-Pierre

Liu et al Cell. 2022 Aug 16. pii: S0092-8674(22)00

Jan. 24, 2024

Academic Institutions and Nonprofits only

#185386-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-GRAB_OT1.0 (#185386). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_OT1.0 plasmid DNA. hSyn-driven expression of the genetically-encoded fluorescent oxytocin(OT) sensor GRAB_OT1.0 in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Qian et al Nat Biotechnol. 2023 Jan 2. doi: 10.1038

June 26, 2024

Academic Institutions and Nonprofits only

#135424-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-jYCaMP1s (#135424). In addition to the viral particles, you will also receive purified pAAV-syn-jYCaMP1s plasmid DNA. Synapsin-driven expression of calcium sensor YCaMP1s. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Mohr et al Nat Methods. 2020 May 25. pii: 10.1038/s

July 22, 2020

Academic Institutions and Nonprofits only

#35497-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO C1V1 (t/t)-TS-EYFP (#35497). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO C1V1 (t/t)-TS-EYFP plasmid DNA. EFIa-driven, Cre-dependent, C1V1 (t/t) fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Yizhar et al Nature. 2011 Jul 27;477(7363):171-8. doi

March 30, 2018

Academic Institutions and Nonprofits only

#113050-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-GRAB_DA1h (#113050). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_DA1h plasmid DNA. Synapsin-driven expression of GRAB-DA1h dopamine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Cell. 2018 Jul 12;174(2):481-496.e19. do

Nov. 4, 2019

Academic Institutions and Nonprofits only

#137955-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.iAChSnFR (#137955). In addition to the viral particles, you will also receive purified pAAV.CAG.iAChSnFR plasmid DNA. CAG-driven iAChSnFR acetylcholine sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Borden et al bioRxiv 2020

Oct. 28, 2021

Academic Institutions and Nonprofits only

#135635-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-S5E2-Gq-P2A-dTomato (#135635). In addition to the viral particles, you will also receive purified pAAV-S5E2-Gq-P2A-dTomato plasmid DNA. Expression of Gq-DREADD and dTomato (physically separate) under the control of the E2 regulatory element. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#131002-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO mScarlet (#131002). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO mScarlet plasmid DNA. EF1a-driven, Cre-dependent mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2024

Academic Institutions and Nonprofits only